Physician profile
Shashank Bhatt
NPI 1023189818
$11,524.47
in general payments reported to CMS, 2019-2025
60 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $509 · 2021: $1,361 · 2022: $2,013 · 2023: $2,281 · 2024: $2,549 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,488.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,093.84 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,008.01 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $771.69 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $741.65 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $695.48 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $687.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $597.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.69 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $502.27 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $365.09 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $340.01 | 2023-2025 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $240.26 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbott Laboratories | $224.33 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $219.89 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.53 | 2020-2025 | Xifaxan, Trulance |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $187.25 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Alnylam Pharmaceuticals INC. | $185.79 | 2022-2025 | Givlaari |
| Sumitomo Pharma America, INC. | $177.72 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $172.72 | 2021-2025 | Korlym |
| Currax Pharmaceuticals LLC | $166.75 | 2022-2025 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $162.44 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $158.86 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.44 | 2022 | |
| Amarin Pharma, INC. | $131.41 | 2020-2022 | |
| Orexo US, INC. | $128.36 | 2022-2024 | Zubsolv |
| Idorsia Pharmaceuticals US INC | $112.30 | 2022-2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $110.67 | 2021-2023 | |
| Insulet Corporation | $93.76 | 2024-2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $84.71 | 2024 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $83.58 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $82.43 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.94 | 2021-2025 | Caplyta |
| Alk-Abello, INC | $71.26 | 2024 | Grastek, Odactra, Ragwitek |
| Corium, LLC | $69.42 | 2023-2024 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $63.41 | 2021 | |
| Paratek Pharmaceuticals, INC. | $63.31 | 2022-2024 | Nuzyra |
| Grifols USA, LLC | $55.97 | 2020-2021 | |
| Inspire Medical Systems, INC. | $55.66 | 2024-2025 | Inspire |
| Allergan, INC. | $55.43 | 2019-2020 | |
| Dexcom, INC. | $54.87 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $43.68 | 2023-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $42.36 | 2024-2025 | Keveyis, Recorlev |
| Aimmune Therapeutics, INC. | $41.15 | 2024 | |
| Vapotherm INC | $36.98 | 2021 | |
| Supernus Pharmaceuticals, INC. | $31.82 | 2022-2025 | Qelbree |
| Verona Pharma, INC. | $31.32 | 2025 | Ohtuvayre |
| Arbor Pharmaceuticals, INC. | $30.84 | 2021 | |
| Mylan Specialty L.P. | $29.35 | 2019-2021 | |
| Ardelyx, INC. | $28.99 | 2025 | Ibsrela |
| Intuitive Surgical, INC. | $27.26 | 2022 | |
| Daiichi Sankyo INC. | $26.85 | 2023 | Injectafer |
| Genentech USA, INC. | $26.31 | 2019 | |
| Lundbeck LLC | $20.59 | 2024 | Rexulti |
| Boston Scientific Corporation | $15.15 | 2022 | |
| Medtronic, INC. | $14.78 | 2023 | Inpen Smart Insulin Delivery System |
| Genzyme Corporation | $14.76 | 2023 | |
| Ibsa Pharma INC. | $13.66 | 2025 | Tirosint, Flector, Licart |
| Tolmar, INC. | $13.42 | 2023 | |
| Collegium Pharmaceutical, INC. | $13.25 | 2024 | Xtampza |
| Janssen Pharmaceuticals, INC | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.